title: Bladder cancer cells acquire competent mechanisms to escape Fas-mediated apoptosis and immune surveillance in the course of malignant transformation.
abstract: Mechanisms of resistance against Fas-mediated cell killing have been reported in different malignancies. However, the biological response of immune escape mechanisms might depend on malignant transformation of cancer cells. In this study we investigated different mechanisms of immune escape in 2 well-differentiated low-grade (RT4 and RT112) and 2 poorly differentiated high-grade (T24 and TCCSUP) bladder cancer cell lines. Fas, the receptor of Fas-ligand, is expressed and shedded by human transitional bladder carcinoma cell lines RT4, RT112, T24 and TCCSUP. Cytotoxicity and apoptosis assays demonstrate that in spite of the Fas expression, poorly differentiated T24 and TCCSUP cells are insensitive towards either recombinant Fas-ligand or agonistic apoptosis-inducing monoclonal antibody against Fas. In poorly differentiated T24 and TCCSUP cell lines we were able to detect marked Fas-ligand protein by flow cytometry and Western blot analysis. In grade 1 RT4 and RT112 cells only minor expression of Fas-ligand possibly because of proteinase action. Fas-ligand mRNA translation or post-translational processing seems to be regulated differentially in the cancer cell lines depending on malignant transformation. In co-culture experiments we show that poorly differentiated cells can induce apoptosis and cell death in Jurkat cells and activated peripheral blood mononuclear cells. This in vitro study suggests that bladder cancer cells can take advantage of different mechanisms of immune evasion and become more competent in avoiding immune surveillance during transformation to higher-grade malignant disease.
authors.affiliation: Department of Urology, Rheinische Friedrich-Wilhelms-University Bonn, Bonn, 53105, Germany.
authors.forename: F G
authors.initials: FG
authors.lastname: Perabo
authors.forename: S
authors.initials: S
authors.lastname: Kamp
authors.forename: D
authors.initials: D
authors.lastname: Schmidt
authors.forename: H
authors.initials: H
authors.lastname: Lindner
authors.forename: G
authors.initials: G
authors.lastname: Steiner
authors.forename: R H
authors.initials: RH
authors.lastname: Mattes
authors.forename: A
authors.initials: A
authors.lastname: Wirger
authors.forename: K
authors.initials: K
authors.lastname: Pegelow
authors.forename: P
authors.initials: P
authors.lastname: Albers
authors.forename: E C
authors.initials: EC
authors.lastname: Kohn
authors.forename: A
authors.initials: A
authors.lastname: von Ruecker
authors.forename: S C
authors.initials: SC
authors.lastname: Mueller
mesh_terms: D000911:Antibodies, Monoclonal / Q000494:pharmacology; D017209:Apoptosis / Q000502:physiology*; D002295:Carcinoma, Transitional Cell; D002455:Cell Division; D002470:Cell Survival / Q000187:drug effects; D002471:Cell Transformation, Neoplastic; D018920:Coculture Techniques; D053222:Fas Ligand Protein; D005434:Flow Cytometry; D006801:Humans; D019169:Jurkat Cells; D008562:Membrane Glycoproteins / Q000235:genetics / Q000494:pharmacology / Q000502:physiology*; D020133:Reverse Transcriptase Polymerase Chain Reaction; D001749:Urinary Bladder Neoplasms; D019014:fas Receptor / Q000276:immunology / Q000502:physiology*
chemical_list: D000911:Antibodies, Monoclonal; C505661:FASLG protein, human; D053222:Fas Ligand Protein; D008562:Membrane Glycoproteins; D019014:fas Receptor